<DOC>
	<DOCNO>NCT01202903</DOCNO>
	<brief_summary>This study ass efficacy , safety tolerability omalizumab , compare placebo 18 75 year old Chinese patient moderate severe persistent allergic asthma inadequate asthma control despite treatment accord GINA ( 2009 ) Step 4 therapy .</brief_summary>
	<brief_title>Omalizumab Patients With Moderate Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA ( 2009 ) Step 4 Therapy</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Met study drugdosing table eligibility criterion ( serum baseline total IgE level ≥ 30 ≤ 700 IU/mL body weight &gt; 20 kg ≤ 150 kg ) Diagnosed asthma ≥ 1 year duration Screening , history asthma adequately control GINA ( 2009 ) Step 4 therapy Received mediumtohigh dose inhaled corticosteroid &gt; 500 µg Beclomethasone Diproprionate ( BDP ) , equivalent plus regularly inhaled LABA , either separately combination , least 8 week prior screen Met specific asthma exacerbation eligibility criteria prior screening period Exhibited inadequate symptom control demonstrate specific criterion ( keep GINA 2009 guideline ) Positive skin prick test least one perennial aeroallergen document historical test within 12 month prior screen , Visit 1 FEV1 ≥ 40 % &lt; 80 % predict normal value patient ( use local standard ) , withhold bronchodilator Visit 2 Used investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer . For biological agentbased investigational drug , monoclonal antibody , least six month need pass last administration drug patient 's Screening Visit . History malignancy History allergy disease could interfere analysis Clinically significant abnormality 12lead ECG record Visit 1 Elevated IgE level reason allergy Current smoker , former smoker smoke history &gt; 10 packyears . A former smoker must abstain minimum 12 month randomization Receiving specific medication Clinically significant laboratory abnormality ( associate study indication ) Visit 1 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>omalizumab</keyword>
	<keyword>asthma</keyword>
	<keyword>immunoglobulin E</keyword>
	<keyword>IgE</keyword>
</DOC>